Clinical outcome of tricuspid valve replacement in children aged no more than 14 years
- VernacularTitle:14 岁及以下儿童三尖瓣置换的临床疗效分析
- Author:
Yaojun DUN
1
;
Haining SUN
1
;
Jun YAN
1
;
Zhongdong HUA
1
;
Shoujun LI
1
Author Information
1. Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, 100037, P.R.China
- Publication Type:Journal Article
- Keywords:
Tricuspid valve replacement;
children;
Ebstein anomaly;
treatment;
surgery
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2020;27(11):1298-1302
- CountryChina
- Language:Chinese
-
Abstract:
Objective To summarize the clinical characteristics and outcome of tricuspid valve replacement (TVR) in children aged no more than 14 years, and to discuss the selection of prosthesis. Methods From September 2002 to August 2019, 14 patients aged no more than 14 years who received TVR were included in our study. There were 9 males and 5 females, with a mean age of 9.8±4.3 years. Results Mechanical prosthesis was implanted in 8 patients, and bioprosthesis in 6 patients. The mean cardiopulmonary time and aortic-clamp time was 170.3±109.8 min and 95.1±63.1 min, respectively. The mortality within 30 days after surgery was 21.4% (3/14), and all 3 patients died of severe low cardiac output syndrome. Eleven patients were followed up for 34-199 (100.1±57.4) months. During the follow-up, mechanical prosthesis dysfunction occurred in 3 patients, 2 of whom received secondary TVR. One patient died during the follow-up. Conclusion The bioprosthesis is the first choice for TVR in children. Some long-term complications may occur after TVR, and close follow-up and timely intervention are needed.
